ReviewMenopause (New York, N.Y.)2017
Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.
Review in Menopause (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Laser and radiofrequency for treating genitourinary syndrome of menopause in breast cancer survivors: A systematic review of randomized controlled trial.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Pooled it
- Cancer therapy-related vaginal toxicity: its prevalence and assessment methods-a systematic review.Journal of cancer survivorship : research and practice · 2025Pooled it
- The effects of various therapies on vulvovaginal atrophy and quality of life in gynecological cancer patients: a systematic review.Archives of gynecology and obstetrics · 2024Pooled it
- Management of Primary Ovarian Insufficiency Symptoms in Survivors of Childhood and Adolescent Cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2018Pooled it
- Five-Year Incidence of Urinary Incontinence in 68,066 Breast Cancer Patients Followed in Gynecology Practices in Germany.Diseases (Basel, Switzerland) · 2025Article
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review.Biomedicines · 2025Review
- Psychometric Evaluation of the Chinese Version of the Vulvovaginal Symptom Questionnaire in Women With Breast Cancer.Journal of advanced nursing · 2025Article
- Vaginal health in breast cancer survivors: a practical clinical approach.Therapeutic advances in medical oncology · 2025Review
- Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options.Medicina (Kaunas, Lithuania) · 2024Review
- Clinical Practice Strategies to Address Sexual Health in Female Cancer Survivors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- Review
- Vaginal Laser Treatment for the Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Narrative Review.Cureus · 2023Review
- Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Emerging Use of Vaginal Laser to Treat Genitourinary Syndrome of Menopause for Breast Cancer Survivors: A Review.Medicina (Kaunas, Lithuania) · 2023Review
- The Effect of Radiofrequency Therapy on Sexual Function in Female Cancer Survivors (Gynecologic and Breast) and Non-cancer Menopausal Women: A Single-Arm Trial.Journal of lasers in medical sciences · 2023Article
- Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Current Perspectives on the Role of Laser Therapy.International journal of women's health · 2023Review
- Management of genitourinary syndrome of menopause in breast cancer survivors: An update.World journal of clinical oncology · 2022Review
- Art of prevention: The importance of dermatologic care when using aromatase inhibitors.International journal of women's dermatology · 2021Review
- Relationship of menopausal symptoms and ovarian reserve in reproductive-aged cancer survivors.Journal of cancer survivorship : research and practice · 2020Article
- Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy.Journal of the National Comprehensive Cancer Network : JNCCN · 2020Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveBreast cancer survivors often take hormonal treatments to prevent the recurrence of breast cancer, particularly aromatase inhibitors that can worsen the symptoms of genitourinary syndrome of menopause (GSM) such as dyspareunia, dysuria, and urinary incontinence, all of which may adversely affect survivors' quality of life. Few breast cancer survivors experiencing GSM receive adequate assessment or treatment.
methodsIn this descriptive study, we reviewed medical records for documented GSM and any treatments administered or referrals for treatment in 800 female patients who visited the Breast Cancer Survivorship Clinic at a comprehensive cancer center between July 1, 2010 and June 30, 2011, either at least 5 years after completion of treatment for invasive breast cancer or at least 6 months after completion of treatment for ductal carcinoma in situ.
resultsOf the 279 patients with documented symptoms of vaginal atrophy, only 111 (39.8%) had documentation of having received any form of treatment or referral. Of the 71 patients with documented symptoms of urinary tract atrophy, only 33.8% had documentation of having received treatment or referral for treatment.
conclusionBreast cancer survivors often experience GSM due to lack of estrogen. The worrisome lack of documentation of assessment or treatment for GSM in a large breast cancer survivorship practice reveals missed opportunities to improve quality of life. Dissemination of recent progress in the development of GSM assessment tools, patient handouts, and new treatments to providers who care for breast cancer survivors is needed to improve this process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.